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Plasmid-based transient human stromal cell-derived
factor-1 gene transfer improves cardiac function in
chronic heart failure
S Sundararaman1,2, TJ Miller3, JM Pastore3, M Kiedrowski1, R Aras3 and MS Penn1,2,3,4
We previously demonstrated that transient stromal cell-derived factor-1 alpha (SDF-1) improved cardiac function when delivered
via cell therapy in ischemic cardiomyopathy at a time remote from acute myocardial infarction (MI) rats. We hypothesized that
non-viral gene transfer of naked plasmid DNA-expressing hSDF-1 could similarly improve cardiac function. To optimize plasmid
delivery, we tested SDF-1 and luciferase plasmids driven by the cytomegalovirus (CMV) promoter with (pCMVe) or without
(pCMV) translational enhancers or a myosin heavy chain (pMHC) promoter in a rodent model of heart failure. In vivo expression
of pCMVe was 10-fold greater than pCMV and pMHC expression and continued over 30 days. We directly injected rat hearts with
SDF-1 plasmid 1 month after MI and assessed heart function. At 4 weeks after plasmid injection, we observed a 35.97 and
32.65% decline in fractional shortening (FS) in control (saline) animals and pMHC-hSDF1 animals, respectively, which was
sustained to 8 weeks. In contrast, we observed a signiﬁcant 24.97% increase in animals injected with the pCMVe-hSDF1 vector.
Immunohistochemistry of cardiac tissue revealed a signiﬁcant increase in vessel density in the hSDF-1-treated animals
compared with control animals. Increasing SDF-1 expression promoted angiogenesis and improved cardiac function in rats with
ischemic heart failure along with evidence of scar remodeling with a trend toward decreased myocardial ﬁbrosis. These data
demonstrate that stand-alone non-viral hSDF-1 gene transfer is a strategy for improving cardiac function in ischemic
cardiomyopathy.
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INTRODUCTION
Heart failure is one of the leading causes of morbidity and mortality in
Western countries. Heart failure has a US prevalence of 5.4 million
Americans and an incidence of 690000 new cases per year.1 Chronic
ischemic damage via myocardial infarction (MI) causes signiﬁcant loss
of cardiac function and often leads to symptomatic heart failure after
treatment with current guideline-based medical therapy. There is a
growing interest in the use of cell and gene transfer to prevent cardiac
dysfunction and treat patients with ischemic heart disease. The
potential of several different cell types for the treatment of cardio-
vascular disease has been studied in animal models and in clinical
populations, including heterogeneous whole bone marrow prepara-
tions,2,3 hematopoietic bone marrow stem cells,4,5 mesenchymal stem
cells,6,7 multipotent adult progenitor cells8 and endogenous cardiac
stem cells populations.9 Many of these studies have shown improve-
ment in cardiac function and have demonstrated an increase in
vascular density within the infarct zone after treatment.
We previously identiﬁed stromal cell-derived factor-1 (SDF-1, also
known as, CXCL12) as a chemokine that is transiently expressed
post-tissue injury to promote stem cell homing to the myocardium.10
SDF-1 enhances tissue repair by preventing cell death and recruiting
blood borne and tissue-speciﬁc stem cells to the damaged region.10
SDF-1 is a naturally occurring chemokine that is rapidly increased
after MI for a period of 4–5 days.10,11 SDF-1 triggers a number of
protective molecular cascades that are both anti-inﬂammatory12 and
anti-apoptotic to preserve cardiac tissue after injury.13 Furthermore,
SDF-1 is a strong chemoattractant of stem cells and progenitor
cells that promote tissue preservation and blood vessel development.
The tissue-preserving and reparative effects of SDF-1 led us to
investigate the potential role of SDF-1 in treating ischemic cardio-
vascular disease.
More recently, we have demonstrated that the overexpression of
SDF-1 in myocardial tissue leads to recruitment of endogenous cardiac
stem cells to the infarct border zone.14 Since our original ﬁndings,
several groups have expanded the molecular mechanisms by which
myocardial expression of SDF-1 or its receptor CXCR4 leads to
preservation of cardiac myocytes and improvement in cardiac func-
tion in an acute MI setting.15,16 We hypothesized that reestablishing
stem cell homing by increasing SDF-1 expression via non-viral gene
transfer into the periinfarct tissue, late after MI, would reestablish
myocardial healing through recruitment of bone marrow-derived stem
cells and lead to increases in vascular density and cardiac function.10
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www.nature.com/gtTo date, we have reestablished SDF-1 expression through a cell-
based gene transfer approach using stably transfected ﬁbroblasts,10
mesenchymal stem cells7 or skeletal myoblasts transfected with an
adenovirus-encoding SDF-1 ex vivo.17,18 Although cell-based gene
transfer is a viable option, the goal of this study was to determine if
reestablishing myocardial SDF-1 expression without the concomitant
delivery of cells is a viable strategy for increasing myocardial vascular
density and cardiac function in the setting of ischemic cardiomyo-
pathy. SDF-1 protein, in combination with a slow release matrix, has
been shown to improve cardiac function in a model of ischemic
cardiomyopathy.19 Although these data would suggest that SDF-1
alone may be sufﬁcient to improve cardiac function, such a conclusion
is premature, as matrix alone has been shown to induce ventricular
remodeling.20,21
To deliver SDF-1 to the myocardium, we injected naked plasmid
DNA encoding hSDF-1 into the infarct border zone. In previous
studies, this strategy has proven to be safe and non-toxic, and is not
associated with the toxicities and loss of function that have been
observed with adenoviral injection in the infarct border zone.22 We
characterized plasmid expression in cardiac tissue using a luciferase
bioluminescence reporter system,23 as previous non-viral gene transfer
studies demonstrated low-transfection efﬁciency with this approach.
We tested plasmid dose, transcription enhancers and ubiquitous
versus cardiac-speciﬁc promoters to increase vector expression. After
identifying an optimal plasmid formulation, we injected plasmid-
encoding SDF-1 into the heart 1 month after MI. This led to a
signiﬁcant increase in cardiac function at 4 weeks after injection that
could be attributed to signiﬁcant increase in vessel density and a trend
toward reduction in scar tissue. The degree of functional improvement
correlated with the level of vector expression.
RESULTS
pCMVe demonstrates high level in vitro expression
The inefﬁciency of physical delivery of non-viral plasmid DNA to cells
has been well documented. One of the strategies used to circumvent
low transfection efﬁciencies has been to identify vector components
that provide either high levels of protein expression or enable target-
speciﬁc expression using tissue-speciﬁc promoters. We tested three
different plasmids in the H9C2 myoblast cell line to identify a vector
that would produce sufﬁcient cardiac cell expression over approxi-
mately 2 weeks. Plasmids were constructed with either the ubiquitous
cytomegalovirus (CMV) promoter or cardiac-speciﬁc a myosin heavy
chain (MHC) promoter and the luciferase reporter genes (pCMV,
pMHC and pCMVe, Figure 1a). We observed that CMV-driven
promoters (pCMVand pCMVe) exhibited higher luciferase expression
compared with the cardiac-speciﬁc aMHC-driven plasmid (pMHC).
As expected, the RU5 translational enhancer in pCMVe increased
expression over pCMV and pMHC by 125 and 250%, respectively,
(Figure 1b).
We assessed in vivo vector expression in adult Lewis rats infarcted
via a left anterior descending artery (LAD) ligation followed by direct
cardiac injection with 100ml of 1mgml 1 pCMV, pMHC or pCMVe-
luc in saline into the anterior wall of the normal myocardium. Control
rats were injected with saline. Gene expression was quantiﬁed by
measuring chemiluminescence following i.p. injection of luciferin
3 days after direct cardiac injection (Figure 1c).
Dose–response of cardiac gene transfer
To determine the optimal plasmid dose required for efﬁcient myo-
cardial transfection, we injected naked plasmid encoding luciferase
(pCMV-luc) into the anterior wall of Lewis rats at doses ranging from
Figure 1 (a) Schematic of the vector design. Vector design of pCMV, pCMVe and pMHC. (b) HEK293 cells were transfected with pCMV and pCMVe, whereas
H9C2 cardiac myoblasts were transfected with pMHC. (c) Cardiac bioluminescence after direct injection. Animals were injected with vectors immediately
following LAD ligation and then imaged 3 days after, following an i.p. injection of luciferin.
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imaging data of all injected plasmids demonstrated that expression
was localized to the cardiac region in all rats (Figure 1c). A dose–
response curve was generated for vector expression. The peak expres-
sion increased up to a dose of 100mg and saturated at higher doses
(Figure 2a). Therefore, a dose of 100mg was used in all subsequent
experiments.
Time course of vector expression in the heart
Next we determined duration of expression after cardiac gene transfer
with pCMV, pCMVe and pMHC vectors. All plasmids expressed
luciferase in infarcted cardiac tissue. Expression from the CMV-
based plasmids expressed for a short period of 5 days, whereas plasmid
pMHC expressed for a longer period of 32 days. Adding elements to
increase transcriptional and translational efﬁciency signiﬁcantly
affected the expression proﬁle, with pCMVe expression lasting
15 days. Changing the promoter or adding elements to increase
translational efﬁciency signiﬁcantly affected the duration of expression
(Table 1).
Comparison of peak magnitude between the different plasmids
The magnitude of luminescent intensity was determined for the three
plasmids (pCMV, pCMVe and pMHC). We observed that pCMV
peaked at day 3. pMHC showed maximum expression on day 7 and
continued for 30 days (Figures 2b and c). The aMHC promoter had a
smaller magnitude of luciferase expression when compared with CMV
promoters. Compared with pCMV, the RU5 translational enhancer in
the CMV plasmid (pCMVe) increased peak expression almost 10-fold
(Figure 2c).
Intra-myocardial injection of SDF-1 plasmid increased vessel
density
Previous studies have shown that SDF-1 expression is increased after
MI and recruits stem and/or progenitor cells to promote tissue
preservation and promote vasculogenesis. We tested whether non-
viral gene transfer of vector expressing SDF-1 would improve vascu-
logenesis following MI. As described above, rodents were infarcted via
LAD ligation and received direct injection of SDF-1 plasmid DNA 1
month after MI. Myocardial sections obtained from animals that
received SDF-1 gene transfer, 8 weeks after injection, were stained with
antibodies against von Willebrand factor to assess vasculogenesis. We
observed a statistically signiﬁcant increase in blood vessel density in
the infarct zone in the animals that received pCMVe-hSDF-1 and
pCMV-hSDF-1, as compared with saline controls (Po0.0001). The
infarct border zone and infarct zone, on average, had a higher blood
vessel density in the pCMVe-hSDF-1 group (21vessels mm 2)a n d
pCMV-hSDF-1 group (17vessels mm 2) than those in the saline
group (6vesselsmm 2)( n¼7 in all groups) (Figure 3a). The vessels
observed by von Willebrand factor staining were also co-stained with
a-smooth muscle actin. A colocalization of endothelial cells and actin
ﬁlaments was observed (data not shown), which further established
the fact that the blood vessels observed were arterioles and arteries,
and not capillaries.
Interestingly, the pCMVe vector that had the highest peak expres-
sion did not induce signiﬁcantly greater vasculogenesis than the lesser
expressing unenhanced pCMV vector. This result suggests that deli-
vering a minimum threshold amount of SDF-1 was necessary to
induce vasculogenesis but that more SDF-1 did not induce more.
SDF-1 plasmid therapy increases left ventricular function in
ischemic rats
We hypothesized that the SDF-1 plasmids that induced vasculogenesis
would also improve cardiac function after MI. To test this hypothesis,
ischemic hearts were injected with hSDF-1 pDNA vectors. Pre-injec-
tion (1 month after infarct), all rats had fractional shortening (FS)
o30%. At 4 weeks after injection, control animals had a decrease in
FS by 35.9%. In contrast, the pCMV-SDF1 and pCMVe-SDF1
groups showed statistically signiﬁcant improvements of 4.62 and
24.97%, respectively, by 4 weeks, (Po0.01) compared with control.
In contrast, a cardiac-speciﬁc promoter, aMHC-driven plasmid
Figure 2 (a) Dose–response of cardiac gene expression. Rodent hearts were
injected with varying doses of pCMV-Luc into the anterior wall. The
chemiluminescence emitted was measured everyday for 5 days after the
injection. (b) Comparison of cardiac bioluminescence between vectors.
Animals were injected with pCMV Luc (n¼5), pCMVe Luc (n¼3) and pMHC
Luc (n¼7) and expression monitored by quantifying the chemiluminescence
emitted. (c) Duration of vector expression. The peak chemiluminescence
exhibited by the vectors is shown here. pCMV-Luc (n¼5), pCMVe-Luc (n¼3)
and pMHC-Luc (n¼7). *Po0.05.
Table 1 Summary of expression proﬁles of vectors studied
Promoter Backbone Enhancer Model Peak expression Days of
expression
aMHC pBS None Infarcted rats 6.75 105 32
CMV pcDNA 3.1 CMV Infarcted rats 2.39 106 5
CMV pcDNA 3.1 CMV+RU5 Infarcted rats 2.75 107 16
Abbreviations: aMHC, a myosin heavy chain; CMV, cytomegalovirus.
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Gene Therapy(pMHC-hSDF1)-treated animals did not improve function compared
with control animals exhibiting a decline in FS of 32.65% (Figure 3b).
These changes in cardiac function, as determined by FS were sustained
to 8 weeks after injection of the respective plasmids (Figure 3c).
Importantly, the improvement in cardiac function correlated with an
increase in blood vessel density, strongly suggesting a link between
vasculogenesis and cardiac functional improvement. However, the
greater beneﬁt seen with the pCMVe compared with pCMV suggests
that there are other mechanisms in action as well, as pCMVe did not
induce greater vascular density compared with pCMV. SDF-1 gene
transfer induced cardiac beneﬁt was sustained at 8 weeks, as the
animals that received the CMV-driven plasmids continued to
demonstrate improved cardiac function compared with saline control
and aMHC vector groups.
Other parameters of cardiac function, such as the thickening of the
anterior and posterior walls, trended toward signiﬁcant improvement
(i.e., an increase in wall thickness) in the pCMVe-hSDF1-treated
animals. No signiﬁcant change was observed in the pCMV-hSDF1-
treated animals, the pMHC-SDF1-treated animals or the saline control
animals. There was no change in left ventricular (LV) mass in any
group by echocardiograrphy.
As the animals treated with the plasmid producing the highest peak
expression had the largest cardiac beneﬁt, these data suggest the
importance of the magnitude of hSDF-1 vector expression rather
than the length of plasmid expression in determining improvement in
cardiac function.
SDF-1 gene transfer reduced ﬁbrotic tissue in the infarct zone
We performed hematoxylin and eosin and Masson’s Trichrome stain-
ing to determine the infarct size, represented by ﬁbrotic tissue, 8 weeks
after treatment with plasmids. The infarct size was reduced in the
animals that received SDF-1 plasmid when compared with the saline
animals. The ﬁbrotic area was smaller in the pCMVe-SDF1 group
(16.92%) and pCMV-SDF1 group (17.81%), than in the saline group
(23.82%) (n¼7 in all groups). These results exhibit a strong trend
toward reduction in cardiac ﬁbrosis following SDF-1 treatment
(P¼0.08) (Figures 4a and b).
DISCUSSION
Regenerative medicine has signiﬁcant potential for the treatment of
ischemic cardiac disease because, unlike current treatments that focus
on either alleviating symptoms or reducing cardiac workload, regen-
erative medicines provide an opportunity to repair and retain function
in degenerating organs. Non-viral gene delivery, or the application of
naked plasmid DNA to express a therapeutic protein at a speciﬁc site,
is a simple delivery method that has been tested clinically in ischemic
patients for over 15 years. A substantial body of literature, both
preclinical and clinical, has demonstrated that non-viral vector
delivery of therapeutic genes is safe and effective. The safety proﬁle
of non-viral gene delivery is attractive when compared with viral
vector therapy delivery because neither it produces a signiﬁcant
inﬂammatory response that viral vector delivery can cause nor is
there concern for antibody response to the vector due to previous viral
exposure in the patient.
Cardiovascular gene therapy has been found to be a safe strategy to
obtain transient protein expression in the heart. Skeletal and cardiac
muscles have been shown to take up and express plasmid-encoded
genes as well as transgenes incorporated into viral vectors.24,25
Although viral vectors provide increased transfection efﬁciencies
compared with non-viral strategies, they induce inﬂammatory
responses that may result in unwanted side effects and preclude repeat
administrations.26 In vitro and in vivo studies have also shown that
despite the lower gene-transfer efﬁciency with non-viral methods, site-
speciﬁc administration of the gene still results in physiological effects
within the local tissue.27,28 Some advantages of non-viral gene transfer
are the ability for repeat administration of therapy and the potential
for transient protein expression. Several clinical trials have demon-
strated safety and efﬁcacy for non-viral gene therapy in ischemic
cardiovascular disease.29
We previously identiﬁed SDF-1 as a naturally occurring protein that
is rapidly produced in response to ischemic tissue injury.11 SDF-1
induction stimulates a number of protective anti-inﬂammatory
Figure 3 SDF-1 gene transfer improves cardiac function through increased
angiogenesis. At 8 weeks after plasmid injection, animals were killed and
the hearts processed for immunohistochemistry. Slides were stained for von
Willebrand factor and ventricular myosin for blood vessels and myocytes,
respectively, in the infarct zone after injection with SDF-1 plasmid in the
pCMV- and pCMVe-treated animals. (a) Vessel density was signiﬁcantly
increased in the SDF-1-treated animals when compared with control
animals. pCMVe-SDF1, 21±1.82vessels mm 2;p C M V - S D F 1 ,
17±1.48vessels mm 2 and saline controls 6±0.73vessels mm 2.
*Po0.001, n¼7 in all groups. (b) Echocardiographic assessment following
plasmid injection. Pre-injection (1 month after infarct), all rats had a
fractional shortening (FS) o30%. At 4 weeks after injection, the control
group (n¼10) decreased in FS by 35.97±11.08 CMV-driven plasmids
showed a statistically signiﬁcant improvement of 4.32±26.10% (pCMV-
SDF1) (n¼9) and 24.97±28.87% (pCMVe-SDF1) (n¼10), respectively,
**Po0.05. The cardiac-speciﬁc promoter plasmid (pMHC-SDF1) (n¼9) did
not improve function compared with control. (c) Comparative analysis
between the percentage of FS at 4 and 8 weeks. The improvement in
cardiac function, as observed at 4 weeks was sustained at 8 weeks after
injections.
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Gene Therapypathways, is increased in the myocardium after a heart attack, but only
lasts for a matter of days, and therefore the protective response quickly
fades. This short duration of SDF-1 action reduces the potential for
tissue repair. A non-viral plasmid-producing SDF-1 for treatment of
heart failure provides a potentially safe means throughwhich to obtain
longer, although transient (o15 day), therapeutic protein production
in the heart, whereas allowing for the possibility of repeat injections.
In this study, we have demonstrated that the delivery of SDF-1
plasmid to the infarct border zone, 1 month after MI, led to an
increase in vascular density and improvement in cardiac function that
was sustained 8–10 weeks after gene transfer. Our expression studies
demonstrated that expression of our optimized plasmid peaked at day
2 after gene transfer and decreased over the following 2 weeks. These
ﬁndings are consistent with previous literature showing a peak in
CMV-driven gene expression, 2 days after injection in the rat
heart.30,31 Peak expression in the presence of the RU5 element
(pCMVe) was 10-fold greater than that seen in the non-enhanced
CMV plasmid (pCMV).
It is noteworthy that direct injection of plasmids into the anterior
wall led to the transfection of cardiac myocytes. In our studies with
plasmid delivery restricted to cardiac myocytes, using the cardiac-
speciﬁc aMHC promoter, there was a delay of 4 days after plasmid
injection, before any evidence of signiﬁcant expression. Furthermore,
the magnitude of expression was 10-fold less than that observed with
the pCMV. Although the signal was low, expression persisted for 32
days. This suggests that combining the aMHC promoter with the RU5
translational enhancer may result in signiﬁcant plasmid expression for
up to 1 month after injection.
The degree of functional changes with any given plasmid-encoding
hSDF-1 correlated with the level of luciferase expression achieved with
that plasmid construct. We observed continued decline in cardiac
function in the animals that received saline or the low-expressing
aMHC plasmid (pMHC). At 4 weeks after plasmid injection (8 weeks
after MI), there was a decline in cardiac function in both these groups,
which correlated with low-expression proﬁles. Both CMV vectors
resulted in an increase in cardiac vascular density. However, the
animals that received the CMV plasmid with enhancer elements
(pCMVe) increased cardiac function to a greater extent than those
animals that received the CMV plasmid alone (pCMV).
Increased SDF-1 expression in the infarct border zone also led to a
decrease in myocardial ﬁbrosis at 8–10 weeks after plasmid injection.
Similar to the change in vascular density, there was an inverse
correlation between the degree of myocardial ﬁbrosis and SDF-1
expression, suggesting that the mechanisms behind scar remodeling
may be crucial to the understanding of the therapeutic response to
SDF-1. These data suggest that SDF-1 treatment attenuates the
progression of chronic ischemic heart failure and may partially reverse
manifestations of the disease by increasing vasculogenesis, reducing
scar formation and attenuating pathological cardiac remodeling
after MI.
MATERIALS AND METHODS
Vector preparation
pCMV-Luc was created by inserting a luciferase cDNA generated by PCR from
a pGL3 vector (Promega, Madison, WI, USA) using primers, forward: 5¢-GA
ATTCGTCGACTATGGAAGACGCCAAAAA CATAAAGAAAGGC-3¢; reverse:
5¢-TCTAGAAAGCTTTTACACGGCGATCTTTCCGCCCTTC-3¢,a tt h eEcoRI
and XbaI sites and ligated it pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA,
USA). The luciferase gene from pCMV was digested with SalI/HindIII and
ligated into a pBSK-aMHC vector (a kind gift from Jeffery Robbins Lab at the
Figure 4 Massons Trichrome staining for collagen content. Left ventricular ﬁbrosis declined in the pCMVe-SDF1 group (a) and pCMV-SDF1 group
(b) compared to the saline group (c)( n¼7 in all groups). SDF-1 gene therapy reduced infarct size 8 weeks after treatment in chronic heart failure.
(d) Decrease in ﬁbrotic scar following SDF-1 treatment. This correlates to a–c. The left ventricular ﬁbrotic area was smaller in the pCMVe-SDF1
(16.92±2.82%) and pCMV-SDF1 groups (17.81±2.59%), compared to the saline group (23.82±4.47%) (n¼7 in all groups), #P¼0.08, demonstrating a
trend towards reduced scar tissue following plasmid injections.
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to generate the pMHC-Luc vector. The aMHC promoter is a mouse aMHC
promoter in pBluescript SK(+) vector (Stratagene, Agilent Technologies, La
Jolla, CA, USA) with a 23bp linker region and a human growth hormone poly
A tail. The pCMVe Luc plasmid was generated by inserting the Luc cDNA into
the pCMVe vector, which contains a CMV enhancer region, CMV promoter,
CMV exon/intron/A region and an RU5 enhancer sequence, followed by a
multi-cloning site and a BGH polyA tail. The human SDF-1 gene was cloned
from the mRNA of human foreskin ﬁbroblasts using the primers, forward:
5¢-GCTAGCGTCGACATGAACGCCAAGGTCGTGGTCGTGCTGGTC-3¢;r e v e r s e :
5¢-AAGCTTTTACTTGTTTAAGGCTTTCTCCAGGTACTCCTGAAT-3¢.T h eLuc
gene was subcloned out of the pcDNA 3.1(+) vector and the SDF-1 cDNA
was inserted in by using a NheI/HindII digest, to generate the pCMV SDF-1; and
used SalI/HindIII to generate the pMHC SDF-1. The pCMVe SDF-1 vectors were
derived by performing PCR of the SDF using the primers. Forward: 5¢-G
CTAGCGTCGACAAGCTTGCCACCACCATGAACGCCAAGGTCGTGGTC-3¢;
reverse: 5¢-TCTAGATTACTTGTTTAAGGCTTTCTCCAGGTACTCCTGAAT-3¢,
digesting with HindIII/XbaI and ligating into the pCMVe. Plasmid DNA was
prepared using the PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen) as
per the manufacturer’s instructions.
Cell transfection and luciferase expression
Plasmids were transfected into HEK293A cells or H9C2 cardiomyoblasts at
50% conﬂuence at 300000 cells per well in a six-well plate using the FUGENE
Transfection kit (Roche, Basel, Switzerland) as per the manufacturer’s instruc-
tions. The cells were exposed to luciferin at 10mg per ml of PBS per well and
the chemiluminescence emitted was quantiﬁed using a cooled couple device
camera from the Xenogen Imaging Systems (Alameda, CA, USA).
Experimental animals
All animal experiments were approved by the Institutional Animal Care and
Use Committee and followed the guidelines provided by them. All animals were
8 weeks old, weighing 200–225grams, Lewis rats (Jackson Laboratories, Bar
Harbor, ME, USA) for the chronic heart failure study. DNA (500mg) was
diluted into PBS for a total volume of 500ml. Sample (400ml) was used for each
animal with 100ml per injection site, for four injection sites, at the border zone.
LAD ligation
Brieﬂy, LAD ligation was performed in rats anesthetized with sodium pento-
barbital, 50mgkg 1. Animals were intubated and ventilated with room air at
100 breaths per minute using a rodent ventilator (Harvard Apparatus,
Holliston, MA, USA). The chest was sterilized with ethanol, and a sternotomy
was performed. The left atrium was retracted and the proximal LAD was
identiﬁed visually. The proximal LAD was ligated using 6-0 prolene (Ethicon,
Somerville, NJ, USA). We were able to verify ligation of the LAD by blanching
and dysfunction of the anterior wall. The sternum and then skin was closed
with 4-0 prolene (Ethicon) with interrupted sutures. Any residual pneumo-
throrax was reduced using negative pressure generated by a 20-G needle placed
in the closed chest, attached to a 10ml syringe. The rat was then weaned from
the ventilator over the next 10–15min.
Intramyocardial gene delivery
To inject the DNA, the chest was reopened 4 weeks after MI, applying the same
procedure as above. DNA (100mg) solution in 100ml of saline per injection site
was injected using a 30-gauge needle, for a total of four injection sites around
the border zone. The border zone was identiﬁed by the blanched region around
the LAD identiﬁed by dyskinetic motion of the anterior wall. The DNA was
injected into the wall and distention of the tissue was observed when the DNA
was injected. The chest was closed as mentioned above for the LAD ligation.
Animal imaging
To determine the optimal plasmid dose required for efﬁcient myocardial
transfection, we injected naked plasmid DNA-encoding luciferase (pCMV-
luc) immediately after ligation of the LAD in Lewis rats. Plasmid injections in
various doses ranging from 0 to 500mg of plasmid in a total volume of 100mli n
saline were administered in the infarct border zone, which was identiﬁed by the
blanching of the tissue. The luciferin substrate for chemiluminescent imaging
was administered intraperitoneally. The animals were routinely measured for
luciferase expression using a cooled couple device camera from the Xenogen
Imaging Systems. The animals were anesthetized using 2% isoﬂuorane and
luciferin was injected i.p. at a concentration of 125mgkg 1 of the animal.
After 10min, real-time images were obtained to determine the whole-body
chemiluminescence of luciferase expression.
Physiological analysis of left ventricular function
We routinely perform 2-D echocardiography on rats using a 15-MHz linear
array transducer interfaced with an Acuson Sequoia C256 (Siemens, Munich,
Germany). The animals were sedated with ketamine, the chest was shaved and
the sedated animal maintained in a supine position. For quantiﬁcation of LV
dimensions and wall thickness, we digitally record 2-D clips and m-mode
images in a short-axis view from the mid-LV just below the papillary muscles.
This anatomical location was chosen to consistently obtain measurements from
the same anatomical location in different mice. Measurements were taken
ofﬂine by using ProSolv (Indianapolis, IN, USA). Each measurement in each
animal was made six times, from three randomly chosen m-mode clips out of
ﬁve. As a measure of LV functions, shortening fractions was calculated from
m-mode studies.
Shortening fraction: (LVEDD-LVESD)/LVEDD 100 where,
LVEDD, LV end-diastolic dimension;
LVESD, LV end-systolic dimension.
Dimensions were measured between the anterior and the posterior walls
from short-axis view just below the papillary muscle. LV mass was calculated by
LV mass¼1.05 ((anterior wall thickness+LVEDD+posterior wall thick-
ness)3 LVEDD3).
Immunohistochemistry
At the time of necropsy, 8 weeks after the injection of the plasmid, the animals
were perfused with saline and histochoice (AMRESCO, Solon, OH, USA) and
the hearts were collected. The hearts were ﬁxed in histochoice for 7 days and
then embedded in parafﬁn. Hearts were then sectioned and stained with
hemotoxylin and eosin staining for identifying the infarct. Mason’s trichrome
was used to quantitate the collagen content. Fibrosis size or scar tissue was
deduced by the percentage of area with collagen as compared with the total
area. Tissues were ﬁxed in formalin and embedded in parafﬁn blocks according
to established protocols. Antigen retrieval was performed using 10mM sodium
citrate buffer (pH 6.0) and heat at 951C for 5min. The buffer was replaced with
fresh buffer and reheated for an additional 5min, then cooled for 20min. The
slides were washed in deionized water three times for 2min each. Specimens
were then incubated with 1% normal blocking serum with goat and donkey
serum in PBS for 60min to suppress nonspeciﬁc binding of immunoglobulin
G. Slides were then incubated for 60min with rabbit polyclonal von Willebrand
factor (Abcam, Cambridge, MA, USA) at 1:100 dilutions in blocking buffer
with serum. Myosinwas stained with mouse monoclonal LV myosin (Millipore,
Billerica, MA, USA) at a dilution of 1:10 in blocking buffer with serum.
Optimal antibody concentration was determined by titration. Slides were then
washed with PBS and incubated for 45min, with immunoglobulin G donkey
anti-rabbit Alexa ﬂuor 594 (Molecular Probes, Invitrogen) at 1:800 dilution in
blocking buffer with serum and immunoglobulin G goat anti-mouse Alexa-
Fluor 488 (Molecular Probes, Invitrogen) at 1:800 dilution in blocking buffer
with serum, respectively, in a dark chamber. After washing extensively with
PBS, coverslips were mounted with aqueous mounting medium. (Vectashield
Mounting Medium with DAPI, H-1200; Vector Laboratories, Burlingame, CA,
USA). For arteriole imaging, a mouse monoclonal a-sarcomeric actin antibody
was used at a 1:200 dilution (Sigma, St Louis, MO, USA).
Confocal microscopy
Tissues were analyzed using an upright spectral laser scanning confocal
microscope (Model TCS-SP; Leica Microsystems, Heidelberg, Germany)
equipped with blue argon (for DAPI), green argon (for Alexa Fluor 488) and
red krypton (for Alexa Fluor 594) lasers. Data were collected by sequential
excitation to minimize ‘bleed-through.’ Image processing, analysis and the
extent of colocalization were evaluated using the Leica Confocal software
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Gene Therapy(Leica). Optical sectioning was averaged over four frames, and the image size
was set at 1024 1024pixels. No digital adjustments were made to the images.
Statistical analysis
All results are expressed as mean±s.e.m. Statistical analysis was performed by
using Student’s t-test.
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